A clinical trial to study the effect of G-CSF in sepsis associated immunosupressio
Phase 3
- Conditions
- Health Condition 1: R098- Other specified symptoms and signsinvolving the circulatory and respiratory systems
- Registration Number
- CTRI/2023/03/050862
- Lead Sponsor
- Banaras Hindu University Varanasi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Multi-organ failure more than or equal to 2 systems and persisting for 3days
Exclusion Criteria
Macrophage activation syndrome,ferritin >500mg/dl
Thrombocytopenia associated Mukti organ failure(TAMOF)
Sequential Multiorgan failure
Haematological disease (neoplasm,acute leukaemia) ,transplant patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method As per picu record @SSH mortality among IPMOF is 63%. Mortality is defined as death within 28days of PICU stay. Reduction in mortality from 63% among IPMOF to 33%Timepoint: 7days,14days and at 28days during hospital stay
- Secondary Outcome Measures
Name Time Method Differences in following parameters between 2 groups at various time points during hospitalisation ,organ failure index IL-6,IL-8 , TNF alpha and nosocomial infectionTimepoint: During admitted in picu